Organo Gold is not only a company who believes in the beverages, personal care products, and nutraceuticals they produce, but also in their elite team of OG distributors, whom the company firmly supports in a family like philosophy that allow distributors to support one another on the way to the top. This type of supportive setup is unlike the multitude of other direct marketing companies in existence today, and allows distributors to focus on providing clients with the best adaptogen enhanced beverages and other products available. What exactly is an adaptogen and how can it help promote overall wellness in your mind and body? Visit corpdev.ogmentorship.com to know more.
An adaptogen is a natural supplement which enhances the body’s ability to handle stress and adapt to a variety of pressures. The adaptogen employed by Organo Gold is Ganoderma Luciderma, which is commonly known as Red Reishi mushrooms. Ganoderma Luciderma has been used as a natural wellness promoting agent for thousands of years in different places worldwide. Today, modern science confirms what the ancients inherently knew, Ganoderma Luciderma provides detoxification, increased liver function, and assists in hormone balance, as well as reducing tumor growth and fighting the spread of cancer. With their vast line of coffees, teas, drink mixes, and other products, Organo Gold is dedicated to providing the world with the incredible effects of Ganoderma Luciderma.
As a distributor you can help Organo Gold in its mission to provide those with the wellness promoting herb who need it most, and can make some money in the meantime. With two different pay structures, Organo Gold lets you decide how you’ll reap the benefits of your work, while the company itself can help you start up your Organo Gold business in one of the over fifty companies they service. Follow Organo Gold on twitter.com.
James Dondero, commonly known as Jim Dondero is the Highland Capital Management President and Co-Founder. Highland Capital Management is a firm that deals with investments and are based in Dallas. Apart from James been focused on investments, he is also a renowned philanthropist. He gives through Highland Capital Management. Recently, they focused on finding a partner who would help them come up with a more structured way of advancing and expanding their charitable acts.
Since there annual funds for giving had grown to a huge sum, they wanted to partner with a company that would help them manage these funds well. This is how The Dallas Foundation came on board. Since they had a team of experienced people who specialized in donor services, they were the best suited for this position. Through this partnership, a more structured and effective giving framework was developed. James’ funding is now benefiting courses in Dallas dealing with education, civic acts, and healthcare among others. Read more about James Dondero on Bloomberg.
James Dondero has more than 3 decades of experience when it comes to equity markets and credit. He uses his expertise to grow Highland Capital Management into a solution for credit to investors and companies looking to advance themselves. Some of their products include equity funds that are privately owned, hedge funds, ETFs, CLOs and mutual funds among others. James Dondero holds a chairman position at CCS Medical, NexBank Capital, Cornerstone Healthcare Group Holding and NexPoint Residential Trust.
James Dondero serves as a board member at Southern Methodist University Cox School of Business and Jernigan Capital. Prior to starting Highland Capital Management, James held positions at American Express, Leap Wireless International, and JP Morgan. James has a Bachelor of Science degree in Commerce, where he majored in finance and accounting, which he achieved at the McIntire School of Commerce, University of Virginia. He has Certified Managerial Accountant, Chartered Financial Analyst and Certified Public Accountant certifications. All these credentials make it possible for him to offer calculated advice to his clients. Through the years, he has worked on enhancing his skills further and this is how he became an expert in his line of work. Visit Nexbank.com to know more about James.
Cancer has proven to be one of the most difficult diseases to fight. We spend billions a year trying to cure it, but there are few successful breakthroughs or notable discoveries. This is all changing thanks to the likes of Clay Siegall and his work at Seattle Genetics. He has taken his decades of research and used it to create some of the most successful drug innovations out there. Particularly, his antibody-drug conjugate has been enormously successful and provided patients with a new way to fight cancer. If he continues to succeed we may see an entirely new way of fighting disease.
Decades Of Important Research
Throughout the late 80s and 90s Siegall spent his time working for research institutes with an eye on the possibility of finding a cure for cancer. His research gave him an insight into how cancer grows and how to inhibit that growth in the body, but more importantly it made him familiar with the struggles of cancer patients. He now uses that understanding to develop tools that will help cancer patients better survive the treatments they must undergo.
Breakthroughs Lead To Innovation
When he decided to found Seattle Genetics in the early 2000s, Siegall had decided he was going to find a way to turn his knowledge into an actual drug. His antibody-drug conjugate gave patients a level of care they didn’t have before. Now, patients are finally able to live without the side effects often found in chemotherapy patients. Seattle Genetics has even attracted the attention of many major investors for its ability to produce some of the most successful innovations around. There continues to be great interest in the future of this company.
The Future Is Bright
Seattle Genetics is always on the rise and it has proven to be one of the most prominent biotech companies of our time. As the future continues to favor companies such as this we can only begin to speculate at the influence of Clay Siegall. He’s certainly left an impact we can see, but there is a path to do even more.